The R337H mutation in TP53 and breast cancer in Brazil

Hereditary Cancer in Clinical Practice

Volumn 10, Issue 1, 2012, Pages

  Gomes, Magda C B ^a,b   Kotsopoulos, Joanne ^c   de Almeida, Gutemberg L ^d   Costa, Mauricio M ^d   Vieira, Roberto ^e   Filho, Firmino de A G ^f   Pitombo, Marcos B ^b   F Leal, Paulo R ^b   Royer, Robert ^c   Zhang, Phil ^c   Narod, Steven A ^c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f The Centre of Tumor Treatment   (Brazil)

Author keywords

Adrenal cortical carcinomas; Brazil; Breast cancer; TP53 mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; EARLY DIAGNOSIS; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; PENETRANCE; POLYMERASE CHAIN REACTION;

EID: 84862132985     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-10-3     Document Type: Article

References (16)

1. Malkin D. Li-fraumeni syndrome. Genes Cancer 2011, 2:475-484. 10.1177/1947601911413466, 3135649, 21779515.
2. Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab 1997, 82:2027-2031. 10.1210/jc.82.7.2027, 9215267.
3. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001, 98:9330-9335. 10.1073/pnas.161479898, 55420, 11481490.
4. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 2006, 43:91-96. 2564508, 16033918.
5. Assumpcao JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008, 8:357. 10.1186/1471-2407-8-357, 2631588, 19046423.
6. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugieres L, Vargas FR, Brentani RR, Ashton-Prolla P, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010, 31:143-150. 10.1002/humu.21151, 19877175.
7. Palmero EI, Schuler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008, 261:21-25. 10.1016/j.canlet.2007.10.044, 18248785.
8. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245:96-102. 10.1016/j.canlet.2005.12.039, 16494995.
9. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001, 29:E88-88. 10.1093/nar/29.17.e88, 55900, 11522844.
10. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001, 86:4970-4973. 10.1210/jc.86.10.4970, 11600572.
11. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. 10.1038/ng1093, 12567188.
12. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956. 10.1038/sj.onc.1207305, 14647431.
13. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
14. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, Van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114. 10.1038/sj.ejhg.5201715, 17003841.
15. Achatz MI, Hainaut P, Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. Lancet Oncol 2009, 10:920-925. 10.1016/S1470-2045(09)70089-0, 19717094.
16. Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007, 103:349-353. 10.1007/s10549-006-9378-6, 17063270.